Your name:

.....

Doctor's name:
(who prescribed filgotinib)

.....

Doctor's phone number:

.....

The date you started filgotinib:

.....

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via the Yellow Card Scheme at **https://yellowcard.mhra.gov.uk**, or search for MHRA Yellow Card in the Google Play or Apple App Store.

Tel: +44 (0) 800 731 6789
This phone line is free and can be used Mon-Fri between 9am and 5pm.

Any suspected adverse reactions to filgotinib should be reported to Alfasigma via email to **DrugSafety.UK.Ireland@alfasigma.com** or by telephone: **0800 072 7878**

Please refer to the filgotinib Patient Information Leaflet or the filgotinib Summary of Product Characteristics (SmPC), available via **www.medicines.org.uk/emc**

Patient Alert Card

Keep this card with you at all times.

Safety Information about Jyseleca® (filgotinib) for patients.

This card contains important information for patients about the safety of filgotinib. Please read the Patient Information Leaflet (PIL) for more information.

Keep this card with you at all times while taking filgotinib and show this card to any healthcare provider involved in your care or treatment, for example a pharmacist or A&E doctor.

Further medical information can be obtained by emailing **medicalinfo@alfasigma.com** or by telephone on **0800 072 7878**

ALFASIGMA

UK

Infections

- Filgotinib may worsen an existing infection or increase your chances of getting a new infection. Tell your doctor straight away if you become ill or notice signs of infections, such as:
  - Fever or chills, shortness of breath, cough, feeling more tired than usual – these may be signs of pneumonia
  - Fever, sweating, weight loss or a cough that won't go away – these may be signs of tuberculosis (TB)
  - A painful skin rash with blisters – this may be a sign of shingles (herpes zoster)
- Before starting filgotinib, tell your doctor if you have had shingles (herpes zoster) in the past as filgotinib can allow it to come back.
- Before starting filgotinib, ask your doctor if you should be tested for TB, including inactive infection.
- Tell your doctor if you have ever had or have recently been in close contact with a person with TB.

Blood clots in leg veins or lungs

- Tell your doctor straight away if you get symptoms of blood clots in your legs or lungs, such as a painful swollen leg, chest pain or shortness of breath.

Pregnancy, contraception and breast-feeding

- Filgotinib must not be taken during pregnancy:
  - Use effective contraception while taking filgotinib and for 1 week after you take your last dose
  - If you become pregnant while taking filgotinib, or think you may be pregnant, stop taking filgotinib and talk to your doctor right away
  - If you are planning to become pregnant, talk to your doctor beforehand
- Do not breast-feed while you are taking filgotinib.

Cholesterol

- High cholesterol is an important risk factor for heart disease. Whilst you are taking filgotinib, your doctor will check your cholesterol levels. This will help decide if you need treatment to lower your cholesterol levels.

Vaccines

- You should not be given certain vaccines, called live vaccines, whilst or immediately prior to taking filgotinib.
- Talk to your doctor or pharmacist about vaccines before starting filgotinib. They may want to make sure you are up to date with your vaccinations.

Cancer and skin cancer

- Filgotinib may lead to an increased risk of cancer. Examine skin periodically and tell your doctor if you discover any new growth on your skin.

Heart disease

- Filgotinib may lead to an increased risk of certain heart diseases. Contact your doctor immediately if you experience chest pain or tightness (which may spread to arms, jaw, neck and back), shortness of breath, cold sweat, light headedness, sudden dizziness, weakness in arms and legs or slurred speech.

If you have any questions about your treatment, speak to your doctor.

Date of preparation: July 2025
GB--FIL-202507-00008